CIK 0001737287
- Non-accelerated filer
- Smaller reporting company
Allogene Therapeutics, Inc.
Sign in to watch- Ticker
- ALLO
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 823562771
- Phone
- +1 650-457-2700
- Business address
- 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- 4 Open-market sale EVP of R&D sold 35,700 shares at $1.77 ($63,189)
- 4 Derivatives Options or other derivatives
- 4 Open-market sale EVP of R&D sold 26,269 shares at $1.56 ($40,980)
- 4 Option exercise Director acquired 47,700 shares (option exercise)
- 4 Open-market sale SVP, Chief Technical Officer sold 786 shares at $1.22 ($959)
- 4 Open-market sale CHIEF FINANCIAL OFFICER sold 36,744 shares at $1.26 ($46,169)
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Planned sale Director sold 36,885 shares at $1.42 ($52,377)
- 4 Open-market sale SVP, Finance sold 9,601 shares at $1.41 ($13,537)
- 4 Open-market sale President and CEO sold 46,668 shares at $1.96 ($91,469)
- 4 Open-market sale SVP, Chief Technical Officer sold 5,488 shares at $1.98 ($10,839)
- 4 Grant or award SVP, Chief Technical Officer acquired 31,755 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Planned sale Director sold 13,313 shares at $2.43 ($32,351)
Page 2 of 14 · 275 filings